menu
    • menu

    Company profile for Molecure

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Molecure is a clinical stage biotechnology company that uses its world leading medicinal chemistry and biology capabilities to discover and develop first-in-class small molecule drug candidates that directly modulate the function of RNA and underexplored protein targets to treat multiple incurable diseases. Our extensive in-house expertise has allowed us to collaborate with top global academic research institutes to access un...
    Molecure is a clinical stage biotechnology company that uses its world leading medicinal chemistry and biology capabilities to discover and develop first-in-class small molecule drug candidates that directly modulate the function of RNA and underexplored protein targets to treat multiple incurable diseases. Our extensive in-house expertise has allowed us to collaborate with top global academic research institutes to access untapped, novel biology targets.Our most advanced in-house drug candidate is OATD-02, an oral, potent and selective first-in-class, dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    MolecurePoland Flag
    Country
    Country
    Poland
    Address
    Address
    Żwirki i Wigury 101, 02-089 Warsaw
    Telephone
    Telephone
    +48 (22) 552 67 24
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://molecure.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/molecure-sa/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/molecure_sa

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Molecure's strategic update on key clinical projects in 2024
    Molecure's strategic update on key clinical projects in 2024

    28 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/28/3051432/0/en/Strategic-update-on-the-progress-and-development-of-Molecure-s-key-clinical-projects-in-2024.html

    GLOBENEWSWIRE
    28 Mar 2025
    Share Share
    Molecure & Ocean Bio Sign Licensing Agreement For YKL-40 Inhibitors
    Molecure & Ocean Bio Sign Licensing Agreement For YKL-40 Inhibitors

    15 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/15/2963070/0/en/Molecure-WSE-MOC-and-Nasdaq-listed-biotechnology-company-Ocean-Biomedical-NASDAQ-OCEA-sign-an-exclusive-licensing-agreement-for-the-development-and-commercialization-of-selective-Y.html

    GLOBENEWSWIRE
    15 Oct 2024
    Share Share
    Avicenna And Molecure Sign Research Collaboration Agreement
    Avicenna And Molecure Sign Research Collaboration Agreement

    31 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240730846334/en

    BUSINESSWIRE
    31 Jul 2024
    Share Share
    Molecure Approved For OATD-01 Pulmonary Sarcoidosis Phase 2 In EU, Norway
    Molecure Approved For OATD-01 Pulmonary Sarcoidosis Phase 2 In EU, Norway

    21 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/21/2885616/0/en/Molecure-receives-approval-to-initiate-a-Phase-II-clinical-trial-KITE-for-OATD-01-for-the-treatment-of-pulmonary-sarcoidosis-in-selected-countries-of-the-European-Union-and-Norway.html

    GLOBENEWSWIRE
    21 May 2024
    Share Share
    Molecure has Published Its Financial Report for 2023
    Molecure has Published Its Financial Report for 2023

    03 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/03/2856657/0/en/Molecure-has-published-its-financial-report-for-2023-the-company-has-significantly-accelerated-the-development-of-its-clinical-and-pre-clinical-programmes-and-plans-to-make-strong-.html

    GLOBENEWSWIRE
    03 Apr 2024
    Share Share
    First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in PS
    First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in PS

    22 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/03/22/2850783/0/en/First-patient-in-the-UK-is-dosed-in-the-OATD-01-Phase-2-KITE-study-in-pulmonary-sarcoidosis.html

    GLOBENEWSWIRE
    22 Mar 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search